Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Shares in Bayer AG fell in opening trade on Wednesday after a U.S. Justice department brief recommended that the Supreme Court reject a company appeal to review a case linking its Roundup weedkiller to a type of cancer.

Bayer shares plunge after U.S. Justice Department asks Supreme Court to reject Roundup appeal

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, the Crop Science Division Stefan Oelrich - Head, the Pharmaceuticals Division Conference Call Participants Vincent Andrews - Morgan Stanley Pete Verdult - Citigroup Sachin Jain - Bank of America Michael Leuchten - UBS James Quigley - Morgan Stanley Keyur Parekh - Goldman Sachs Falko Friedrich - Deutsche Bank Christian Faitz - Kepler Cheuvreux Steve Byrne - Bank of America Richard Vosser - JPMorgan Operator Ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the First Quarter 2022 Results.

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q1 2022 Results - Earnings Call Transcript

Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1

Agriculture and pharmaceuticals company Bayer reported quarterly adjusted core earnings rose a better-than-expected 27.5% on strong gains at its seeds and pesticides business.

Bayer's farming business drives Q1 earnings beat

Shareholders of Bayer on Friday voted to reprimand the German drug and farming supplies maker for its top management pay scheme, after one leading proxy advisory group said it did not adequately reflect Bayer's litigation burden.

Bayer gets shareholder rebuke for management remuneration

German diversified group Bayer has seen a "very successful start to the year", driven by a favourable environment in agricultural markets, it said on Monday.

Bayer says start to the year very successful thanks to agriculture unit

Norway's $1.3 trillion wealth fund will cast a vote in support next week of top management at German drug and farm products maker Bayer AG, but will vote against the remuneration package of CEO Werner Baumann, it said on Sunday.

Norway's sovereign fund will vote to support Bayer management

Ginkgo Bioworks Holdings

MONHEIM, Germany--(BUSINESS WIRE)--Bayer today announced that the company is pursuing an agreement whereby Ginkgo Bioworks will acquire Bayer's West Sacramento Biologics Research & Development (R&D) site and internal discovery and lead optimization platform. The contemplated transaction, projected to close before the end of 2022 pending final negotiation of the agreement terms and subject to regulatory approvals, would also bring Joyn Bio's nitrogen-fixing technologies to Bayer, success

Bayer to Create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology Platforms

AbbVie

Two health care companies most investors might not be familiar with were among the four biggest stock market gainers in the first quarter, according to an analysis by Evaluate.

AbbVie and Bayer Record Hefty Share Price Gains in 1st Quarter

Bayer's technical picture improved in the last few months, and the company also reported solid fiscal 2021 results.

Bayer: Still A Buy

Apple

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Apollo Investment

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Preferred Apartment Communities

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Brookfield Infrastructure Partners L.P.

Bank of Montreal

The war in Ukraine continues to dominate market movements. I am not selling anything and predominantly focus on adding dividend income via select purchases.

My Dividend Stock Portfolio: March 2022 Update - 101 Holdings And 29 Buys

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today late-breaking data from prespecified exploratory subgroup analyses of FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials. These analyses investigated KERENDIA® (finerenone) versus placebo on composite cardiovascular (CV) and kidney outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), with and without a history of atherosclerotic cardiovascular disease (ASCVD).

Bayer Presents New Subgroup Analyses for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without History of Atherosclerotic Cardiovascular Disease

Deutsche Bank

The DAX index made a spectacular recovery in the first quarter in sync with other top indices. It rose by more than 16% from its lowest level this year even as risks to the German economy remained.

Here are the best DAX index constituents in Q1

LEVERKUSEN, Germany--(BUSINESS WIRE)--Today, Bayer held its first ever Breakthrough Innovation Forum, focusing on longer-term opportunities for health and agriculture leveraging emerging technologies. The event followed Bayer's recent short- and mid-term pipeline updates for its Pharma and Crop Science Divisions and shared further insights on Bayer's ongoing progress to drive long-term breakthrough innovations in the Life Sciences. Renowned experts and Bayer executives illustrated how a forthco

Bayer Set to Drive Breakthrough Innovations in the Life Sciences

German drugmaker Bayer said it would invest around 2 billion euros ($2.23 billion) at pharmaceutical manufacturing sites over the next three years, mainly to bolster production of biotechnology drugs as well as cell and gene therapies.

Bayer to invest 2 billion euros in drug production over next 3 years

LITTLE ROCK, Ark.--(BUSINESS WIRE)--Windstream President and CEO Tony Thomas today announced that Buddy Bayer has been named to lead a newly combined Enterprise and Wholesale organization, effective immediately. Bayer, who joined the company in 2014, has been serving as chief network officer and president of Windstream Wholesale. In his new role as president of the Enterprise and Wholesale Business Unit, Bayer will be responsible for sales and marketing, service delivery, customer care, service

Windstream Names Buddy Bayer to Lead Combined Enterprise, Wholesale Organization

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer to Highlight New Cardiovascular and Renal Data at ACC.22

Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program

Bayer shareholder Union Investment on Monday came out in support of the drugmaker's chief executive serving out his full term after the CEO came under renewed pressure over the company's performance.

Bayer shareholder Union Investment says CEO should stay on

Bayer AG reached an $80 million settlement with Ohio to resolve environmental damage allegedly caused by polychlorinated biphenyls, or PCBs, made by the company's Monsanto business, the state attorney general said on Thursday.

Bayer reaches $80 million PCB contamination settlement with Ohio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock

SAN FRANCISCO--(BUSINESS WIRE)--Woebot Health has secured a $9.5 million investment from Leaps by Bayer. The strategic funding marks Leaps by Bayer's first in mental health.

Woebot Health Secures $9.5 Million Investment From Leaps by Bayer

Germany's Bayer on Monday stopped all spending in Russia and Belarus not related to essential products in health and agriculture, citing Russia's "brutal aggression" against Ukraine.

Bayer stops non-essential health and agriculture business in Russia

Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.

Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B

Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.

Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer and Cinven have entered into a definitive agreement regarding the sale of Bayer's Environmental Science Professional business for a purchase price of 2.6 billion U.S. dollars (2.4 billion euros), Bayer announced on Thursday. “This divestment represents a very attractive purchase price and allows us to focus on our core agricultural business and the successful implementation of our Crop Science Division growth strategy,” said Rodrigo Santos, Member of

Bayer to Sell Its Environmental Science Professional Business to Cinven for 2.6 Billion U.S. Dollars

News for Bayer AG Stock (BAYRY)